Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Basiliximab - Novartis

Next Previous
Drug Profile

Basiliximab - Novartis

Alternative Names: CHI 621; Chimeric RFT5; chRFT5; SDZ CHI 621; Simulect

Latest Information Update: 03 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Cerimon Pharmaceuticals; Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transplant rejection
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection; Transplant rejection
  • Discontinued Ulcerative colitis; Uveitis

Most Recent Events

  • 22 Sep 2014 Launched prior to this date for Renal transplant rejection in Argentina, Mexico, Canada, Venezuela, Chile, Indonesia, China, Malaysia, Philippines, Singapore, Hong Kong, South Africa, Australia, New Zealand, Belgium, Denmark, Ireland, Finland, France, Germany, Greece, Hungary, Poland, Portugal, Sweden, Czech Republic, Norway, Turkey, Russia & Ukraine (IV)
  • 22 Sep 2014 Launched prior to this date for Transplant rejection in Brazil & Thailand (IV)
  • 01 Mar 2013 Novartis completes its phase II IDEALE trial for Renal transplant rejection in France (NCT01596062)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top